Published in Health Business Week, January 12th, 2007
The company reported that progress continues on the market development of Gen-Probe's test for prostate cancer based on DiagnoCure's PCA3 gene. The test, which scientists believe will be more accurate than existing tests for prostate cancer, received European CE mark status and was launched in Europe in November. "Our partner, Gen-Probe (GPRO),...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.